Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Industry, government, patient advocacy groups, public funders, and academic thought leaders met in Toronto, Canada, to set into motion an initiative that addresses some of the scientific and organizational challenges of modern therapeutics discovery. What emerged from the meeting was a public-private partnership that seeks to establish proof of clinical mechanism (POCM) for selected "pioneer" disease targets using lead compounds-all accomplished in the precompetitive space. The group will reconvene in April 2011 to create a business plan that specifies the generation of two positive POCM results per year.

Original publication

DOI

10.1126/scitranslmed.3002399

Type

Journal article

Journal

Sci Transl Med

Publication Date

30/03/2011

Volume

3

Keywords

Canada, Clinical Trials as Topic, Commerce, Congresses as Topic, Drug Discovery, Government, Humans, Public-Private Sector Partnerships